Ivarmacitinib for the Treatment of Adults with Severe Alopecia Areata: Results from a Phase 3 Trial

    September 2025 in “ Journal of the American Academy of Dermatology ”
    Cheng Zhou, Chunjun Yang, Weixin Fan … Jianzhong Zhang
    Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

    We don't know much about this study yet.

    Read the full study on jaad.org →
    Discuss this study in the Community →

    Research cited in this study 16

    1. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    2. Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis Frontiers in pharmacology · 2024
    3. Janus Kinase Inhibitors for Alopecia Areata Journal of the American Academy of Dermatology · 2023
    4. Janus Kinase Inhibitors For Alopecia Areata JAMA network open · 2023
    5. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    6. Quality of Life in Children and Adolescents With Alopecia Areata: A Systematic Review Journal of the European Academy of Dermatology and Venereology · 2023
    7. Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2022
    8. The Efficacy and Safety of JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis of Prospective Studies Frontiers in pharmacology · 2022
    9. Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2021
    10. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    11. JAK Inhibitors and Alopecia Areata Lancet · 2019
    12. Alopecia Areata: Clinical Presentation, Pathogenesis, and Treatment Options Journal of the American Academy of Dermatology · 2018
    13. Alopecia Areata: A Review of Disease Pathogenesis British journal of dermatology/British journal of dermatology, Supplement · 2018
    14. Alopecia Areata: Treatment Options and Efficacy Journal of the American Academy of Dermatology · 2017
    15. Alopecia Areata: Overview and Insights from January 2018 Journal of The American Academy of Dermatology · 2017
    16. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014